Targeting Treatment of Soft Tissue Sarcomas: Cancer Treatment and Research, cartea 120
Editat de J. Verweij, H.M. Pinedoen Limba Engleză Paperback – 23 mar 2013
- Written by leaders in the industry
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 331.60 lei 38-45 zile | |
Springer Us – 23 mar 2013 | 331.60 lei 38-45 zile | |
Hardback (1) | 331.60 lei 38-45 zile | |
Springer Us – 27 mai 2004 | 331.60 lei 38-45 zile |
Din seria Cancer Treatment and Research
- 5% Preț: 699.55 lei
- 5% Preț: 788.82 lei
- 5% Preț: 1090.81 lei
- 5% Preț: 462.01 lei
- 5% Preț: 633.75 lei
- 5% Preț: 812.41 lei
- 5% Preț: 331.87 lei
- 5% Preț: 1828.22 lei
- 5% Preț: 1222.53 lei
- 5% Preț: 1239.79 lei
- 5% Preț: 941.02 lei
- 5% Preț: 636.30 lei
- 5% Preț: 935.08 lei
- 5% Preț: 920.02 lei
- 5% Preț: 923.49 lei
- 5% Preț: 1209.68 lei
- 5% Preț: 618.42 lei
- 5% Preț: 593.70 lei
- 5% Preț: 650.66 lei
- 5% Preț: 1223.78 lei
- 5% Preț: 944.46 lei
- 5% Preț: 926.31 lei
- 5% Preț: 916.22 lei
- 5% Preț: 928.79 lei
- 5% Preț: 940.39 lei
- 5% Preț: 924.09 lei
- 5% Preț: 1240.41 lei
- 5% Preț: 640.36 lei
- 5% Preț: 1309.79 lei
- 5% Preț: 1242.55 lei
Preț: 331.60 lei
Preț vechi: 349.05 lei
-5%
Puncte Express: 497
Preț estimativ în valută:
63.53€ • 68.82$ • 54.48£
63.53€ • 68.82$ • 54.48£
Carte tipărită la comandă
Livrare economică 06-13 mai
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781475779417
ISBN-10: 1475779410
Pagini: 196
Ilustrații: VII, 184 p.
Dimensiuni: 210 x 279 x 10 mm
Greutate: 0.45 kg
Ediția:Softcover reprint of the original 1st ed. 2004
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research
Locul publicării:New York, NY, United States
ISBN-10: 1475779410
Pagini: 196
Ilustrații: VII, 184 p.
Dimensiuni: 210 x 279 x 10 mm
Greutate: 0.45 kg
Ediția:Softcover reprint of the original 1st ed. 2004
Editura: Springer Us
Colecția Springer
Seria Cancer Treatment and Research
Locul publicării:New York, NY, United States
Public țintă
ResearchDescriere
Recent achievements in the development of new techniques and agents for the treatment of cancer in general as well as for soft tissue sarcomas are tremendous. Molecular biology research has changed the landscape considerably and an increasing number of subtypes of soft tissue sarcomas are related to changes in cellular growth factors in the cell signaling pathways. This enables the development of targeted agents with specific activity against these factors. The presence of the KIT receptor at the surface of the gastrointestinal stroma tumor cell, and the activation constituted by mutations has led to the discovery of an extremely active specific KIT tyrosine kinase inhibitor.
In accordance with the more targeted approach in drug use, the changes in the field of radiation therapy and surgery basically focus on a better targeting of the disease, albeit not yet based on the molecular characteristics. All of these stress the importance of the multidisciplinary approach to the treatment of soft tissue sarcoma that was the focus of previous editions of this book.
Targeting Treatment of Soft Tissue Sarcomas summarizes the recent events in this field, putting the achievements in perspective. Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future.
In accordance with the more targeted approach in drug use, the changes in the field of radiation therapy and surgery basically focus on a better targeting of the disease, albeit not yet based on the molecular characteristics. All of these stress the importance of the multidisciplinary approach to the treatment of soft tissue sarcoma that was the focus of previous editions of this book.
Targeting Treatment of Soft Tissue Sarcomas summarizes the recent events in this field, putting the achievements in perspective. Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future.
Cuprins
Targeted therapy: Ready for prime time?.- Volume-based radiotherapy targeting in soft tissue sarcoma.- Preoperative therapy for soft tissue sarcoma.- TNF-based isolated limb perfusion: A decade of experience with antivascular therapy in the management of locally advanced extremity soft tissue sarcomas.- Pitfalls in pathology of soft tissue sarcomas.- Molecular biology and cytogenetics of soft tissue sarcomas: Relevance for targeted therapies.- KIT and PDGF as targets.- Targeting mutant kinases in Gastrointestinal Stromal Tumors: A paradigm for molecular therapy of other sarcomas.- Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-? in liposarcomas.- Angiogenesis: a potential target for therapy of soft tissue sarcomas.
Recenzii
"The management of soft tissue sarcomas remains a difficult challenge. However, significant advances have occurred in our understanding of the important signaling molecules in these diseases. Experts in the field discuss the critical therapeutic targets and relevant treatment strategies for these malignancies."
(Steven T. Rosen, M.D., Series Editor)
(Steven T. Rosen, M.D., Series Editor)
Caracteristici
Summarizes the recent events in this field, putting the achievements in perspective.
Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future
Physicians and researchers working in the field of soft tissue sarcomas must be aware of the changes in treatment, the underlying concepts, and of the changes we face in the future